Drugs, bugs, and personalized medicine: Pharmacometabonomics enters the ring
暂无分享,去创建一个
[1] A. Duncan,et al. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[2] H. Adlercreutz,et al. Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[3] P. Turnbaugh,et al. Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.
[4] J. Lindenbaum,et al. Interethnic variation in the metabolic inactivation of digoxin by the gut flora. , 1988, Gastroenterology.
[5] C. Svanborg,et al. Intestinal Colonization with Enterobacteriaceae in Pakistani and Swedish Hospital‐Delivered Infants , 1991, Acta paediatrica Scandinavica.
[6] A. Barabasi,et al. Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.
[7] D. Nebert,et al. Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. , 2003, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
[8] I. Wilson,et al. Induction of 5-oxoprolinuria in the rat following chronic feeding with N-acetyl 4-aminophenol (paracetamol). , 1993, Biochemical pharmacology.
[9] I. Wilson,et al. The role of gut microbiota in drug response. , 2009, Current pharmaceutical design.
[10] J. Lindon,et al. Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.
[11] I. Wilson,et al. Physiological variation in metabolic phenotyping and functional genomic studies: use of orthogonal signal correction and PLS‐DA , 2002, FEBS letters.
[12] V. Mathan,et al. Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. , 1989, Gut.
[13] B. Drasar,et al. Diet and faecal flora in three dietary groups in rural northern Nigeria , 1986, Journal of Hygiene.
[14] V. P. Butler,et al. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. , 1981, The New England journal of medicine.
[15] Ian D. Wilson,et al. Metabolic Phenotyping in Health and Disease , 2008, Cell.
[16] M. McCarthy,et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice , 2006, Proceedings of the National Academy of Sciences.
[17] D. Bessesen,et al. Human gut microbes associated with obesity , 2007 .
[18] John C Lindon,et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism , 2009, Proceedings of the National Academy of Sciences.
[19] Jeremy K. Nicholson,et al. Gut microbiota: a potential new territory for drug targeting , 2008, Nature Reviews Drug Discovery.